PBM
LENZ

Propel Bio Management’s LENZ Therapeutics LENZ Stock Holding History

Propel Bio Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-59,085
Closed -$945K – 41
2025
Q4 		$945K Buy
+59,085
New +$1.72M 0.81% 17

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Propel Bio Management's LENZ Position: Q1 2026 in Review

Propel Bio Management sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 59,085 shares — an estimated $945K sold.

Propel Bio Management first reported a position in LENZ in Q4 2025 and held it in 1 quarter. The position peaked at $945K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Propel Bio Management reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Propel Bio Management sold 59,085 LENZ Therapeutics shares in Q1 2026, an estimated $945K.
  • Propel Bio Management first reported a position in LENZ Therapeutics in Q4 2025 and held it in 1 quarter.
  • Propel Bio Management's LENZ Therapeutics position peaked at $945K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.